RASmutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiplemyeloma patient harboring BRAF mutation - Archive ouverte HAL Access content directly
Journal Articles European Journal of Haematology Year : 2020

RASmutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiplemyeloma patient harboring BRAF mutation

(1) , (2) , (3) , (4, 5) , (6) , (7, 1) , (1) , (1) , (1) , (1) , (1) , (2) , (8, 5) , (7, 1) , (2) , (9, 1) , (7, 1)
1
2
3
4
5
6
7
8
9
Céline Bossard
  • Function : Author
  • PersonId : 1029200

Abstract

Multiple myeloma (MM) is still considered incurable and new therapeutic approaches are therefore needed. Deep-sequencing analysis revealed the presence of BRAF mutations in up to 15% of patients. The clinical experience of BRAF-targeted therapy in myeloma patients harboring BRAF mutation is still limited. We here report the case of a patient with penta-refractory (bortezomib, lenalidomide, carfilzomib, pomalidomide, and daratumumab) MM with extramedullary BRAF-mutated disease that achieved clinical response to dual BRAF and MEK inhibition. At the time of disease progression, gene sequencing analysis of the tumor at the time of progression demonstrated a clonal evolution with emergence of aNRAS mutation and persistence of BRAF and TP53 mutations. Backtracking of the NRAS mutation was performed by digital polymerase chain reaction on the baseline biopsy and identified the pre-existence of the NRAS at a subclonal level. This observation is the first report of acquired NRAS mutation leading to resistance to dual BRAF/MEK inhibitors in MM. These data suggest that a systematic search for RAS mutations using highly sensitive techniques should be performed before considering targeted therapy in relapsed myeloma with BRAF mutation.
Fichier principal
Vignette du fichier
jha28_LR-3-1.pdf (9.38 Mo) Télécharger le fichier
Origin : Publication funded by an institution
Loading...

Dates and versions

inserm-02874002 , version 1 (18-06-2020)

Identifiers

Cite

Baptiste Le Calvez, Yannick Le Bris, Guillaume Herbreteau, Bastien Jamet, Céline Bossard, et al.. RASmutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiplemyeloma patient harboring BRAF mutation. European Journal of Haematology, 2020, Online ahead of print. ⟨10.1002/jha2.8⟩. ⟨inserm-02874002⟩
74 View
54 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More